Oramed Pharmaceuticals (ORMP) Income from Continuing Operations (2011 - 2026)
Oramed Pharmaceuticals (ORMP) posted Income from Continuing Operations of 38310000.0 for Q1 2026, up 80.75% on a QoQ basis from 21195000.0 in Q4 2025, and up 601.31% year-over-year from 5462645.45 in Q1 2025.
Oramed Pharmaceuticals (ORMP) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Oramed Pharmaceuticals' Income from Continuing Operations history runs 15 years deep, the most recent figure standing at 38310000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 601.31% year-over-year to 38310000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 121154000.0 (up 528.42% YoY) and the FY2025 annual result came in at 75202000.0, up 493.67% from the prior year.
- Income from Continuing Operations was 38310000.0 for Q1 2026 at Oramed Pharmaceuticals, up from 21195000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 48389000.0 in Q3 2025 and bottomed at 19642000.0 in Q3 2024.
- A 5-year average of 3319058.82 and a median of 3284000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations soared 800.99% — and 2025, when it sank 598.17%.
- Oramed Pharmaceuticals' Income from Continuing Operations stood at 12055000.0 in 2022, then surged by 210.29% to 13296000.0 in 2023, then plunged by 176.71% to 10199000.0 in 2024, then surged by 307.81% to 21195000.0 in 2025, then jumped by 80.75% to 38310000.0 in 2026.
- Business Quant data shows ORMP's Income from Continuing Operations at 38310000.0 in Q1 2026, 21195000.0 in Q4 2025, and 48389000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Oramed Pharmaceuticals | 169.21 Mn | 169.21 Mn | - | 38.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.31 Mn |
| Dec 31, 2025 | 21.20 Mn |
| Sep 30, 2025 | 48.39 Mn |
| Jun 30, 2025 | 13.26 Mn |
| Mar 31, 2025 | -7.64 Mn |
| Dec 31, 2024 | -10.20 Mn |
| Sep 30, 2024 | -19.64 Mn |
| Jun 30, 2024 | 9.20 Mn |
| Mar 31, 2024 | 1.53 Mn |
| Dec 31, 2023 | 13.30 Mn |
| Sep 30, 2023 | -3.28 Mn |
| Jun 30, 2023 | -1.31 Mn |
| Mar 31, 2023 | -3.62 Mn |
| Dec 31, 2022 | -12.06 Mn |
| Sep 30, 2022 | -7.25 Mn |
| Jun 30, 2022 | -12.10 Mn |
| Mar 31, 2022 | -11.65 Mn |
| Aug 31, 2021 | -22.99 Mn |
| Nov 30, 2019 | -2.45 Mn |
| Aug 31, 2019 | 26.43 Mn |